Asterand to Integrate its Quantitative Human Gene Expression Database with BioWisdom’s Integrated Discovery Platform
News Feb 10, 2009
Asterand plc and BioWisdom Ltd have announced that the Companies have entered into a data syndication agreement to provide value added delivery of Asterand’s human gene expression profiles through BioWisdom’s intelligence solutions. Terms of the agreement were not disclosed.
Through this agreement, BioWisdom gains access to the data within Asterand’s proprietary Target Evaluator™ database. The database consists of quantitative human gene expression profiles that chart the expression topography of more than 2,500 commercially relevant gene transcripts across a panel of 72 human tissues. These profiles are systematically generated using high quality human RNA and a sensitive RT-PCR protocol.
BioWisdom will harmonize the data with its software solutions enabling the information to be combined with other public and private sources or utilized independently as raw data or assertional meta data. The harmonized Asterand data are available as an entire dataset or sub-sets of selected targets and tissues.
BioWisdom’s ontology powered intelligence solutions ease the integration and display of data enabling researchers to visually analyze text, numerical, categorical and sequence data in a single integrated environment. As a result, researchers are able to relate divergent data sets to uncover previously unknown associations and answer key scientific questions.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE